Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Intelligence Dataset

Catalyst Tracker

Track upcoming regulatory, clinical, commercial, and strategic events before they impact the market.

3,372 catalysts

Filters

Pro

Intelligence Pro

Unlock Full Catalyst Intelligence

Access the complete catalyst dataset, advanced filtering, exports, historical events, watchlists, alerts, and API access.

3,362 additional catalysts available with Intelligence Pro.

Upgrade to Intelligence ProCompare Plans
DateCompanyAssetEvent TypeStatus
July 24, 2026Novitium PharmaPimozideFDA DecisionFDA DecisionPending
July 24, 2026Micro LabsHydrochlorothiazideFDA DecisionFDA DecisionPending
August 2, 2026MerckKEYTRUDA QLEXFDA DecisionFDA DecisionUpcoming
August 2, 2026MerckWeliregFDA DecisionFDA DecisionPending
August 2, 2026Amphastar PharmaceuticalsREXTOVYCommercial LaunchCommercial LaunchCompleted
August 2, 2026PROD DEVELOPMENTFDA DecisionFDA DecisionUpcoming
August 2, 2026SumatriptanCommercial LaunchCommercial LaunchUpcoming
August 2, 2026MylanDivalproex SodiumCommercial LaunchCommercial LaunchPending
August 2, 2026BayerNDA219627Commercial LaunchCommercial LaunchUpcoming
August 2, 2026UnichemFDA DecisionFDA DecisionPending

Intelligence Pro

Unlock Full Catalyst Intelligence

Access the complete catalyst dataset, advanced filtering, exports, historical events, watchlists, alerts, and API access.

3,362 additional catalysts available with Intelligence Pro.

Upgrade to Intelligence ProCompare Plans
August 2, 2026Alembic PharmaceuticalsTretinoinFDA DecisionFDA DecisionUpcoming
August 2, 2026AllergyFDA DecisionFDA DecisionCompleted
August 3, 2026Regulatory ApprovalCommercial LaunchCommercial LaunchUpcoming
August 3, 2026AbiomedFDA DecisionFDA DecisionUpcoming
August 3, 2026Safety SignalFDA DecisionFDA DecisionUpcoming

Showing 10 of 3,372 catalysts

Pagination and full dataset access require Intelligence Pro.

Priority Window

Upcoming 30 Days

Highest-priority catalysts in the next month.

  • 8.0

    Merck

    KEYTRUDA QLEX · FDA Decision

    August 2, 2026

  • 8.0

    Merck

    Welireg · FDA Decision

    August 2, 2026

  • 7.0

    Amphastar Pharmaceuticals

    REXTOVY · Commercial Launch

    August 2, 2026

  • 7.0

    PROD DEVELOPMENT · FDA Decision

    August 2, 2026

  • 7.0

    Sumatriptan · Commercial Launch

    August 2, 2026

  • 7.0

    Mylan

    Divalproex Sodium · Commercial Launch

    August 2, 2026

  • 7.0

    Bayer

    NDA219627 · Commercial Launch

    August 2, 2026

  • 7.0

    Unichem · FDA Decision

    August 2, 2026